Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Aim(s): The objective of the study was to evaluate efficacy of RAD alone or in combination with somatostatin analogs in human pNETs.
Materials and methods: Measure of cell viability, chromogranin A (CgA) secretion, caspase and Akt activities in 20 human pNETs in primary culture.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: doctor Corinne Gerard
, Romano D
, Poizat F
, Delpero J R
, Niccoli P
, Moutardier V
, Garcia S
, Albertelli M
, Ferone D
, Barlier A
, Saveanu A
, Gerard C
To read results and conclusion, please login ...
Further abstracts you may be interested in